2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

Exact Sciences Corporation73 sites in 3 countries2,150 target enrollmentApril 2, 2018

ConditionsHepatocellular Carcinoma Hepatocellular Carcinoma Surveillance

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hepatocellular Carcinoma
Sponsor: Exact Sciences Corporation
Enrollment: 2150
Locations: 73
Primary Endpoint: Biomarker Identification
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).

Detailed Description

Subjects with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing HCC surveillance will be enrolled and have blood samples collected. Subjects undergoing HCC surveillance will be followed for up to 6 months. Another blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.

Registry

clinicaltrials.gov

Start Date

April 2, 2018

End Date

March 11, 2020

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Exact Sciences Corporation

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•All Subjects:
•Subject is 18 years of age or older
•Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of data, including personal health data, to the study investigator and sponsor
•HCC Subjects:
•Subject has a recent (within 6 months of enrollment) untreated clinically diagnosed hepatocellular carcinoma as defined by ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance and/or capsule by 4 phase CT scan or multiphase contrast enhanced MRI or biopsy is positive for HCC.
•Control Subjects:
•Non-cancer subject undergoing routine imaging surveillance for HCC
•Definitive lack of HCC within 3 months prior to enrollment as defined by negative imaging, for HCC.
•Control Group 1 - negative by ultrasound
•Control Group 2 - negative by CT or MRI

Exclusion Criteria

•Known cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).
•Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
•Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.
•Any HCC treatment prior to enrollment/blood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC).
•IV contrast (e.g. CT and MRI) within 1 day \[or 24 hours\] of blood collection.
•Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
•Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
•Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Outcomes

Primary Outcomes

Biomarker Identification

Time Frame: 1 year

Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects with HCC compared to those without (but are at risk of developing the disease so are under surveillance)